Platform Achievements:

OriCell Therapeutics Presents Exciting Clinical Results of Its First CAR-T Cell Product Targeting Hepatocellular Carcinoma at the ASCO Annual Meeting!

OriCell Therapeutics (Shanghai) Co., Ltd. (referred to as "OriCell Therapeutics"), together with Lishui Central Hospital affiliated to Zhejiang University and Shanghai Changzheng Hospital, presented the updated clinical research data on evaluating CAR-T drug targeting GPC3 (Ori®CAR-001) for treatment of relapsed/refractory hepatocellular carcinoma (HCC) (Abstract ID: 4095) on June 4, 2021 (EST), at the 2021 annual meeting of American Society of Clinical Oncology (ASCO). Preliminary data from the study have shown promising safety and efficacy results of Ori®CAR-001 in patients with GPC3-positive relapsed/refractory HCC.